SMA Research Platform

Evidence graph for Spinal Muscular Atrophy

Biology-first target discovery
Christian Fischer / Bryzant Labs
15,945Targets
453Trials
85Drugs
7Datasets
8,004Sources
221,721Claims
232,882Evidence
73,172Hypotheses
DRUGphase1antibody

adimanebart

Brand names: ARGX-119, adimanebart

Mechanism

First-in-class humanized agonist IgG4 antibody binding MuSK extracellular domain. Activates MuSK → drives AChR clustering and NMJ stabilization. Differs from MG anti-MuSK antagonists.

Related claims (0)

No claims matched “adimanebart” in free-text search.

Off-Target Findings (0)

No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.

Login → Command Center